Amgen makes bid to acquire Nuevolution

22 May 2019

US biotech giant Amgen (Nasdaq: AMGN) today offered to acquire all the shares of its research partner, Copenhagen, Denmark-headquartered Nuevolution (STO: NUE), for a consideration of 32.50 Swedish kronor in cash per share. The total value of the offer corresponds to around 1,610 million kroner or about $167 million.

The offer represents a premium of:

169% compared to the closing price of Nuevolution’s shares on Nasdaq Stockholm on 21 May 2019 (the last trading day prior to the announcement of the Offer), of SEK 12.10; and
69% compared to the highest trading price of Nuevolution’s shares on the Nasdaq Stockholm during the 52-week period up to and including May 21, 2019 (the last trading day prior to the announcement of the offer), of 19.28 kronor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK